The sensitivity of plasma circ-LDLRAD3 combined with CA19-9 in the diagnosis of pancreatic cancer was 80.33%, and the specificity was up to 93.55%, which was significantly higher than that of CA19-9 or circ-LDLRAD3 alone106. Here, LDLRAD3 is linked to pancreatic neoplasm.